A Conversation with Ken Keller, Chairman of the Board President and CEO,  Daiichi Sankyo, Inc.

Key Concepts

• Antibody Drug Conjugates (ADCs): A class of biopharmaceutical drugs designed as a targeted therapy for treating cancer, consisting of an antibody, a linker, and a cytotoxic payload.
• Psychological Safety: Creating an environment where team members feel safe to admit mistakes, report "smoke" (early warning signs) before they become "fire" (major crises), and offer honest feedback.
• Alliance Tax: The additional operational complexity, communication overhead, and coordination effort required when partnering with other organizations.
• Sontaku: A Japanese cultural concept involving tacit communication where subordinates are expected to infer a superior's expectations without explicit instruction.
• Non-negotiables: A set of core leadership principles used to align teams, such as prioritizing the voice of those closest to the customer and maintaining a "zero spin" culture.

---

1. Career Trajectory and Philosophy

Ken Keller, CEO of Daiichi Sankyo Inc., emphasizes that careers are rarely linear or perfectly planned. Starting as an entry-level sales representative at Beecham Pharmaceuticals, he navigated various roles—including district manager, regional manager, and international assignments—before reaching his current executive position.

• Key Inflection Point: Keller identifies a pivotal moment at Amgen when his CEO denied him a promotion because he had failed to develop other leaders. This "gut punch" forced him to shift his focus from individual performance to working through others.
• Career Advice: Keller advocates for "playing in traffic"—taking opportunities as they arise, even if they seem daunting or require relocation (e.g., his move to the UK). He stresses that credibility is a leader's primary currency, built through consistent delivery and integrity.

2. Leadership Frameworks and Culture

Keller manages by a set of "non-negotiables" that he shares with every team he leads:

• Customer Proximity: The individuals closest to the customer or the problem must have the loudest voice in decision-making.
• Open Book Leadership: Leaders must provide granular, descriptive guidance on what "good" and "exceptional" look like.
• Zero Spin Zone: Keller mandates transparency, specifically requesting that teams show "red" and "yellow" lights in reports rather than masking issues. He argues that punishing failure leads to mediocrity, as teams will avoid aiming high to ensure they meet safe, low-bar targets.
• Coaching Moments: He emphasizes that feedback should be immediate and continuous rather than reserved for formal mid-year or end-of-year reviews.

3. Strategic Pivot: From Cardiovascular to Oncology

Daiichi Sankyo underwent a massive strategic transformation, shifting its 100-year focus from cardiovascular disease to oncology.

• The Catalyst: The shift was driven by a drying cardiovascular pipeline, the emergence of innovative ADC technology in the lab (led by Dr. Akatsuma), and the strategic vision of leadership to prioritize high-impact oncology research.
• Partnerships: The company entered into multi-billion dollar collaborations with Merck and AstraZeneca. Keller explains that these were not just financial decisions but strategic necessities to accelerate clinical development. He describes these partnerships as "co-parenting," where the goal is to maximize the "size of the pie" (patient outcomes) rather than protecting a smaller, individual slice.

4. Real-World Applications and Technology

• AI in Pharma: Keller highlights two practical applications:
  1. Efficiency: Using AI to consolidate regulatory filings, reducing the manual workload by approximately 80% for new indications.
  2. Precision Medicine: Utilizing digital pathology and biomarkers to identify specific patient populations that will benefit most from ADCs, potentially increasing response rates significantly.
• Clinical Impact: Keller notes that ADCs have fundamentally changed the prognosis for conditions like HER2-positive metastatic breast cancer, turning a negative prognostic factor into a manageable one.

5. Cross-Cultural Leadership

Keller discusses the nuances of leading a Japanese organization as an American executive:

• Navigating Sontaku: He acknowledges the Japanese cultural tendency toward indirect communication and has learned to adapt by being explicit about his need for direct, transparent feedback.
• Relationship Building: He emphasizes that in Japan, investing time in personal relationships—often outside the office—is a sign of respect and a critical component of building trust within the organization.

---

Synthesis and Conclusion

Ken Keller’s leadership philosophy centers on the belief that leadership is a team sport. By fostering psychological safety, demanding radical transparency, and prioritizing the development of others, he has successfully guided Daiichi Sankyo through a major strategic pivot. His approach highlights that while strategy provides the direction, culture—defined by integrity, collaboration, and the courage to aim high—is what ultimately determines the success of an organization. The core takeaway is that leaders must be intentional about their personal brand and consistently act to lift others up, as the professional world is highly interconnected and reputation is paramount.